General Callout
Nunc dolor esse suscipit eros eros ullamco dolor. Duis velaliquam sunt urna, tempuribud doming quis, laboris ultricies ultricies urna laboris. Nostrud pulvinar nostrud elit sunt ex exercitation magna tempuribud laboris ea ex nunc sed exercitation ea laboris dignissim.
Accordion
Quis harmud ea commodo voluptate dolor urna providerent tempor amet dignissim velit consectetur harmud sint doming, urna magna velit sed commodo urna sint sunt nunc. Nunc consectetur laboris harmud dolore exercitation sed magna laboris nulla velit velaliquam ultricies. Dignissim adipiscing, sed duis ultricies sint voluptate providerent nunc nisi.
Heading 1
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Heading 2
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Call to action
Esse suscipit in eros ea sed voluptate dolore, harmud nisi, dolore ultricies fugiat amet doming ut sint ut adipiscing. Sit velit velaliquam ex nunc ut voluptate
Status:
Concluded with an LOI
Manufacturer:
AbbVie Corporation
Indication:
Schizophrenia in Adults
Last updated March 28, 2023
Status:
Concluded with an LOI
Manufacturer:
Celltrion Healthcare Canada Ltd.
Indication:
Metastatic Colorectal Cancer (mCRC); Locally Advanced, Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC); Platinum-Sensitive Recurrent Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer; Platinum-Resistant Recurrent Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer; and Malignant Glioma (WHO Grade IV) - Glioblastoma
Last updated March 23, 2023
Status:
Concluded with an LOI
Manufacturer:
Hoffmann-La Roche Ltd.
Indication:
Unresectable locally advanced or metastatic extracranial solid tumours, including brain metastases, in adult patients, that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, and with no satisfactory treatment options
Last updated March 16, 2023
Status:
Concluded with an LOI
Manufacturer:
Hoffmann-La Roche Ltd.
Indication:
Non-small cell lung cancer (NSCLC) in adult patients whose tumours have PD-L1 expression on ? 50% of tumour cells (TCs) and do not have EGFR or ALK genomic tumour aberrations, monotherapy for adjuvant treatment following resection and platinum-based chemotherapy, Stage II to IIIA (per the American Joint Committee on Cancer [AJCC], 7th edition)
Last updated March 14, 2023
Status:
Concluded without agreement
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Indication:
Advanced or metastatic breast cancer, Hormone receptor-positive, HER2-negative, PIK3CA mutated, after disease progression following an endocrine-based regimen, in postmenopausal women and men (In combination with fulvestrant)
Last updated March 14, 2023
Status:
Concluded with an LOI
Manufacturer:
Ultragenyx Canada Inc.
Indication:
Long-Chain Fatty Acid Oxidation Disorders
Last updated March 14, 2023
Status:
Concluded with an LOI
Manufacturer:
Sanofi-Aventis Canada Inc.
Indication:
Asthma
Last updated March 10, 2023
Status:
Concluded with an LOI
Manufacturer:
Tanvex BioPharma USA, Inc.
Indication:
Neutropenia in various indications (Prevention or treatment)
Last updated March 10, 2023
Status:
Negotiations were not pursued
Manufacturer:
AbbVie Corporation
Indication:
Diabetic Macular Edema
Last updated March 9, 2023
Status:
Concluded with an LOI
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Indication:
Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) previously treated with two or more tyrosine kinase inhibitors, in adult patients
Last updated March 9, 2023